Ani Pharmaceuticals (ANIP) Revenue Growth (3y) (2013 - 2026)
Ani Pharmaceuticals (ANIP) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 2.94% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 30.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.52% |
| Dec 31, 2025 | 37.89% |
| Sep 30, 2025 | 39.55% |
| Jun 30, 2025 | 41.98% |
| Mar 31, 2025 | 45.14% |
| Dec 31, 2024 | 46.24% |
| Sep 30, 2024 | 41.77% |
| Jun 30, 2024 | 41.60% |
| Mar 31, 2024 | 130.65% |
| Dec 31, 2023 | 31.99% |
| Sep 30, 2023 | 35.51% |
| Jun 30, 2023 | 33.97% |
| Mar 31, 2023 | 28.97% |
| Dec 31, 2022 | 25.24% |
| Sep 30, 2022 | 17.75% |
| Jun 30, 2022 | 10.76% |
| Mar 31, 2022 | 6.83% |
| Dec 31, 2021 | 2.17% |
| Sep 30, 2021 | 0.88% |
| Jun 30, 2021 | 0.95% |